CYBN.E Archives • Page 2 of 2 • ShroomStocks.ca

Investing is a trip

Recent Posts

Revive Therapeutics (RVV.CN) updates on psilocybin study for methamphetamine use
Lophos Pharma (MESC.C) now readies for natural and synthetic peyote production
Peyote at the ready: Lophos Holdings (MESC.C) expands license, lays out product specs
Peyote at the ready: Lophos Holdings (MESC.C) expands license, lays out product specs
Optimi Health (OPTI.C) transforming psychedelic treatment and wellness
Bionxt Solutions (BNXT.C) shows how pivots don’t have to mean resets
Bionxt Solutions (BNXT.C) shows how pivots don’t have to mean resets
Lophos Pharmaceuticals (MESC.C) expands licensing to include just about all the drugs
Lophos Pharmaceuticals (MESC.C) expands licensing to include just about all the drugs
Reveive Therapeutics (RVV.C) finds multiple research options moving forward
Cannabis memory lane: Who’s sticking it out, who’s dead and dying
Lucy Loves Luchre: Psyence Group (PSYG.C) was always just a shroom chaser

Search for:

Post date
September 23, 2021
Posted by
Joseph
Posted in AdvisorShares Psychedelics ETF, atai life sciences, atai.q, cmps.q, cybin, CYBN.E, ETF, field trip, FTRP.T, MindMEd, Morton, Mushrooms, Psychedelics, Revive Therapeutics, RVV.C
Comments
0